

Global Macro Strategy

An EM turnaround? III –Valuation optics vs. reality

Global Macro Strategy

Global

Read the previous two notes in this series:

[An EM turnaround? I –Assessing the anatomy of the rally](#)

[An EM turnaround? II –Have FED/China changed the game for FX and commodities](#)

The valuations issue at its core

Valuations and growth in EM live in completely different post codes of their long-term distributions. This is an issue in DM as well, but is more pronounced in EM. Other than the idea of loose monetary policy 'permanently' altering the NPV profile of EM assets, the only other way to rationalise such dissonance is to hope that growth will 'mean-revert' to much higher levels. We find both theses, shall we say, brave, in the context of structural changes in EM leverage and in patterns of global trade.

Equities: Why that simple P/B chart for EM is a banana skin

The valuation case in favour of EM stocks is typically made through the large gap between EM and DM price to book ratios. We are all for simplicity, but not in this case. When we normalise these ratios for declining return on equity in EM, only three sectors show up as being cheap – energy, financials, and utilities. Unfortunately, these are precisely the sectors where the representation of state owned enterprises is the highest. Given that current return on equity has been propped up by higher leverage, we think it is perfectly rational to discount future prospects. Once we dissect valuations by sector, it's difficult to walk away with the conclusion that EM equities are attractively priced. For things to change, we need better corporate governance, higher asset turns, but more than anything we need better growth. The market expects now 7.7% earnings growth this year. We expect 0-3%. On our earnings estimates, we think MSCI EM fPE is just above 13x, much higher than its long-term average of 11x.

FX: If it ain't fixed, why not keep fixing it?

We have consistently argued that in a world where the beta of global trade to global growth is declining, PPP based FX valuation models will fail to capture the forces that are compromising EM currencies. We have a preference for the FEER approach, but we also pay a lot of attention to export growth, and unit labour cost-adjusted valuations. Very few EM currencies appear misaligned in terms of current accounts. However, they do seem misaligned when viewed in the context of growth and productivity. Despite lower US rates and a more stable oil backdrop, we maintain that EM currencies will depreciate in trade weighted terms this year. We expect GBI-weighted EM currencies to fall c.6% against the USD this year after a 17% decline last year.

Credit: Likely the best performing asset class, but spreads will widen

We base our fair value estimates for spreads on an error correction model which posits EM macro balance sheet scores, commodity prices and global risk premia as the long-term drivers of EM credit. While central banks have aided compression in global risk premia, and commodity prices have found some stability, we find that the compression in EM spreads has been too aggressive given the lack of improvement in EM macro balance sheets. We expect EMBI spreads to widen 50-75 bps into year end. Growth needn't decline further for negative outcomes on credit; the longer that growth stays at the current low levels, the higher the risk of a non-linear widening in spreads.

Local rates: Focus on FX hedged opportunities

In a world where DM yields have been crushed, EM yields, trading slap back in the middle of their post-crisis distribution, are optically compelling. However, credit risk in several EMs has also risen in this period. After accounting for this, we find EM valuations showing significant dispersion but on aggregate falling short of those seen in 2011, H1 2012, and H1 2014 when EM yields saw sustained declines. We prefer rates over FX in Brazil, Mexico, Korea, India, Indonesia, and Hungary.

Bhanu Baweja

Strategist

bhanu.baweja@ubs.com

+44-20-7568 6833

Manik Narain

Strategist

manik.narain@ubs.com

+44-20-7567 3218

Geoff Dennis

Strategist

geoff.dennis@ubs.com

+1-617-748 5622

Alan Alanis

Strategist

alan.alanis@ubs.com

+1-212-713 2204

Maximillian Lin

Strategist

maximillian.lin@ubs.com

+65-6495 8429

Sambuddha Ray

Strategist

sambuddha.ray@ubs.com

+44-20-7568 8307

Howard Park

Strategist

howard.park@ubs.com

+1-212-713 4708

Contents

Warming up: A basic drill	3
Equity valuations: The problem with 'that' chart.....	5
EM FX: If it ain't fixed, keep fixing it.....	13
EM credit: Balance sheet pressures to persist even if commodities stabilise	19
Local rates: Optically appealing, but beware rising credit risk ..	23

Bhanu Baweja

Strategist
bhanu.baweja@ubs.com
+44-20-7568 6833

Manik Narain

Strategist
manik.narain@ubs.com
+44-20-7567 3218

Geoff Dennis

Strategist
geoff.dennis@ubs.com
+1-617-748 5622

Alan Alanis

Strategist
alan.alanis@ubs.com
+1-212-713 2204

Maximillian Lin

Strategist
maximillian.lin@ubs.com
+65-6495 8429

Sambuddha Ray

Strategist
sambuddha.ray@ubs.com
+44-20-7568 8307

Howard Park


Strategist
howard.park@ubs.com
+1-212-713 4708

Warming up: A basic drill

In this note we will delve into important details of how we think about fair value and in different EM asset classes, the influences upon them and their evolution in a world undergoing structural challenges. As a prelude to what can be fairly involved arguments about high and low, then and now, allow us to present a set of 'entry level' charts (Figure 1 to Figure 4) that depict a simple notion.


Why we suffer from mean reversion aversion

Figure 1: Distribution of EM Real GDP growth




Source: Haver, UBS. Bar labels denote % of observations in that bucket. Distribution since 1996.

Figure 2: Distribution of EMBI spreads




Source: Datastream, UBS. Bar labels denote % of observations in that bucket. Distribution since 1998.

Figure 3: Distribution of MSCI-EM P/E



Source: Datastream, UBS. Bar labels denote % of observations in that bucket. Distribution since 1996.

Figure 4: Distribution of EM REERs (2010 = 100)




Source: Haver, UBS. Bar labels denote % of observations in that bucket. Distribution since 1996.

The figures above represent long-term distributions of EM growth and valuation metrics in EM equities, credit and FX. It is clear that while EM growth is in the lower echelons on the first quartile of its 25-year distribution, asset valuations are at or above the median. The same divergence is on display in DM, but is less pronounced there. Apart from loose monetary policy 'permanently' altering the NPV profile of assets, the only other way in which such dissonance can be rationalised is the hope that growth will 'mean-revert' to much higher levels. We find this hope, shall we say, brave, in the context of meaningful changes in EM leverage (Figure 5 and Figure 6) and patterns of global trade (Figure 7).


Valuations and growth reality are in different post codes today. Who is going to travel for them to meet?

Figure 5: Investment to GDP: Investment has soared in EM. How much further can it drive EM growth?



Source: IMF, Haver, UBS

Figure 6: Domestic credit to GDP: the investment has been financed by a serious increase in credit to GDP.




Source: Haver, UBS. EM represents a universe of 66 emerging economies. Red numbers denotes period when Fed began tightening.

Even if growth were to stabilise here, current levels are low enough for there to be a drift weaker in capital flows and asset values (Figure 8). The lack of large USD liabilities diminishes the probability of balance of payments crises, but amidst persistence of weak growth we are building up towards balance sheet issues that tend to ensnare EM economies quicker than DM economies.


The swampland of muddle-through

Figure 7: Global GDP and trade growth: The beta of trade volumes to real growth has fallen back to 1980s levels



Source: Haver, UBS

Figure 8: EM growth premium over DM and total capital flows into EM




Source: Haver, UBS. EM capital flows shown here is GDP weighted average of 22 EM countries.

Equity valuations: The problem with 'that' chart

We've all seen it. It demonstrates simply that valuations are way cheaper in EM than in DM. In a world where DM companies, having had their fill of financial engineering, are no longer able to push up EPS, investors ask why they shouldn't consider cheaper EM assets? In the base case scenario there's little difference in earnings prospects, but one is also buying positive growth optionality for a pittance. And – here is what clinches it for many– this valuation spread against DM always mean reverts. Several analyst graves have 'this time is different' inscribed on their epitaphs, investors warn us.

Simplicity usually is the best policy

Figure 9: The valuation case in EM at its simplest : EM v DM P/B spread over the last 10 years. Simple, elegant, and, in our humble opinion, simplistic



Source: MSCI, Datastream, UBS

These are all good arguments, and we've learnt the hard way that, when it doubt, it really pays to keep things simple. However, in the present instance there is little doubt in our minds that there is plenty under the hood not to be swayed by the elegant façade of wide DM to EM P/B gaps. Below we lay out how we think about EM equity valuations. The key points are

But there is plenty under the surface here that's worth uncovering

- 1) Consensus now expects 7.7% growth in USD earnings for 2016. Our earnings model points to 0-3% earnings. EM P/E valuations are expensive even on a consensus earnings basis. Based on our earnings estimates fP/E is already closer to 13.2x
- 2) On a P/B basis EM valuations seem reasonable. However, this assumes that estimates of book value are correct. We think it is likely that persistent weakness in income statements will impact EM balance sheets, making the present consensus view on B (in P/B) too generous, similar to bloated estimates of E (in P/E) over the last 5 years.
- 3) Rising sectoral variance in valuations weakens the arguments about valuations of EM aggregates, so a call on individual sectors is important.
- 4) The usual practice is to set P/B against RoE. That is interesting today in EM because it shows P/B is not too low. Even more interesting is setting it against RoA, which excludes the leverage support that RoE affords. This shows that P/B may be a little high.

- 5) Sectors where the market is attributing a low price to book despite high RoE are energy and financials. These are sectors which are optically cheap. However, these are also the sectors where the quality of the RoE is poor owing to high fairly SoE representation (58% in energy, 43% in financials).

EM earnings: Can we finally see some positive growth?

Using quarterly data since 1996, we model y/y growth in USD earnings growth for MSCI EM on a) lagged values of export growth, b) lagged valued of industrial production growth, c) change in our macro balance sheet risk score for (MSCI weighted) EM, and d) raw industrial commodity prices. Based on USD export growth of around 7% in 2016 (a big improvement from -10% in 2015), industrial production growth of 5%, flat commodity prices, and a modest worsening of EM macro credit risks as measured by our macro balance sheet risk score, we forecast USD earnings growth of 1.5% in 2016. This is our base case scenario (Figure 10)¹. Note here we are incorporating a reasonably strong numbers for EM growth export and IP growth. A slightly weaker export recovery estimate of about 4% would imply flat earnings this year. Here is the equation for the model

$$\text{y/y Earnings growth} = -1.47 + 0.98 \cdot \text{EXIP}(-2) - 10.47 \cdot \text{D(MBS)} + 0.18 \cdot \text{D(Cmdty)}$$

Where EXIP(-2) is linear combination of exports and industrial output growth, 2 quarters lagged; D(MBS) is the quarterly change in our macro balance sheet risk score, and CRB is the year over year change in industrial commodity prices².

Figure 10: MSCI EM earnings growth forecasts

	Export growth	Industrial growth	Change in raw industrial commodity prices	Change in credit risk*	Earnings growth
Downside	-5%	3%	-20%	0.40	-12.0%
Base case	5%	5%	0%	0.20	1.5%
Upside	12%	7%	20%	-0.20	15.0%

Source: Haver, Datastream, UBS

The rally in EM currencies thus far this year (which has also helped commodities) has prompted revisions 2016 earnings estimates to 7.7%. However, we think that while EM currencies will not sell off against the USD in 2016 as they did in 2015, they will nonetheless weaken by 4-5% (See [An EM turnaround? II –Have FED/China changed the game for FX and commodities](#)). Implicitly then we are arguing for a decent improvement in local earnings, which, it has to be said, has not come to pass as yet.


We believe earnings can and should be forecast on a bottom up basis, but modelling a few macro variables can provide a shortcut that lands us in roughly the right post code, even if not at the doorstep

We still see weaker FX, but reasonable pick up in y/y local earnings growth

¹ Exports and industrial production are correlated, presenting a problem of multicollinearity, and so use a linear combination of these as one explanatory variable. We set up long term model to forecast equilibrium earnings, given other macro variables


² The adjusted Rsq of the regression is 0.834 and the respective t stats associated with the independents are respectively 6.99 for exports and IP, -4.92 for change in macro balance sheet risk score, and 3.83 for yearly change in industrial commodity prices.

Figure 11: EM earnings growth vs. Exports and IP growth (% y/y)



Source: Datastream, UBS

Figure 12: GEM Countries: 1 month vs. 3 months forward earnings revisions (%)




Source: IBES, Datastream, UBS

P/E: Little Value, even with optimistic EPS forecasts

Over the five years to end- 2015, no value opened up in EM equities as a 31% fall in MSCI GEMs was accompanied by a 29% fall in earnings (both in USD). Over this period, any rally tended to push EM equities into expensive territory. Relative to DM, MSCI GEMs has opened up a significant forward P/E discount since the end of 2010, largely because DM equities became richer rather than EM cheaper (Figure 13 and Figure 14). This discount levelled off in a 25-30% range after the end of 2012 and currently stands just above its long-term average of 24%.


Even the consensus earnings based P/E ratio is already above its long-term average

Figure 13: EM, DM Consensus Forward P/E



Source: IBES, UBS

Figure 14: EM/DM Forward P/E Relative



Source: IBES, Datastream, UBS

By sector, the valuation data shows how narrow are the areas of value in EM. Only Financials (which typically trade on P/BV) and Utilities (perennially out of favour) trade below their 20-year average multiples, while IT is at fair value. All other sectors currently trade above their 20-year averages, especially Materials and Consumer Staples.

So, on a P/E basis we really don't see a big valuation case to be made for EM. All claims of EM being cheap really rest on the P/B. That's what we tackle next, but even before we go there one really must ask what might the P/E know that the P/B doesn't? It is that E just isn't coming back in quite the same way. B will get a wind of it soon enough, and change its colours, we think.


On a P/E basis EM looks expensive. On a P/B basis it looks cheap. Why? Because the E knows (no growth), but the B doesn't yet

Where the rubber meets the road – How to think about Price to Book in EM

On a P/B basis EM equities are trading at just 1.42x at end-March, a 23% discount to its long-term average of 1.8x (Figure 15). However, there are two concerns about this apparently positive conclusion:


- These low P/BV ratios must be set against the backdrop of a steady fall in the average EM RoE from 15.2% (one standard deviation above its 20-year mean of 12.1%) in late-2011 to 10.4% at the end of March, which is approaching one standard deviation below this average (Figure 16); and
- We expect Book Values of EM corporates to come under pressure as EM growth continues to slow – or, at least, fails to rebound; as balance sheets come under pressure this will push BVs lower.

Figure 15: MSCI EM P/B ratios



Source: MSCI, UBS

Figure 16: MSCI EM Return on Equity (RoE)




Source: MSCI, UBS

Figure 17 allows us to judge at what P/BV should EM trade, given the current average RoE: the higher the RoE, the higher the P/B ratio. Again, using data back to 1995, the P/BV-RoE fit is much better and suggests, remarkably, that the 'fair value' P/BV, based on the current RoE, for MSCI GEMs is just above today's levels (Figure 17).


Today's P/B levels, even if we were to assume that they are correct, don't seem out of sync when one looks at where RoE is

Figure 17: EM P/B vs. RoE



Source: Bloomberg, Datastream, UBS

Figure 18: EM P/B vs. RoA



Source: Bloomberg, Datastream, UBS

We have made the additional point that the quality of RoE in EM is poor because it has been propped up by high leverage. See ([Theme #6: Simmering trouble – Mapping the path of EM pain](#)). If instead of looking at EM P/B in the context of RoE we were to set it against RoA (which includes margins and assets turns but excludes leverage from RoE) then the current P/B doesn't look cheap at all (Figure 18). That's why we don't like thinking of the plunge in P/B in isolation.

But there's more. How appropriate is it today to make broad comments about EM valuations on an aggregate basis? The higher the variance of a distribution the less one can trust its median. And the variance of EM valuations has been rising. Interestingly, this less true when breaking valuations down by countries; the real increase in variance is coming through in valuations across sectors (Figure 19). This is what we investigate next.

Figure 19: Sectoral variance across MSCI EM : standard deviation of price to book across the 10 GICS sectors



Source: Datastream, UBS


Looking at this P/BV data by sector (Figure 20), there seems to be much more value than was the case for the P/E metrics. In this case, the only sectors *not trading* at a P/BV discount to their 20-year history are Health Care, Consumer Staples and Utilities. All other sectors – Energy, Financials, Materials, IT, Telecoms and, just, Industrials and Consumer Discretionary – currently have a P/BV ratio below their long-term averages.

Good news? Not so fast. If the same chart is drawn for sector RoEs (Figure 21), the only sectors currently carrying an RoE above their 20-year averages are Utilities and (just) IT, with Financials, Health Care and Consumer Staples close to their averages. Pulling these two charts together, the only sector with a bullish combination of below-average P/BV and above-average RoEs is IT, although the Utilities sector has an above-average RoE with a smaller premium on P/BV.

The persistent decline in E which is likely to infect B, and the big decline in RoE and RoA makes the decline in P/B look, if anything, modest


The only sector with a bullish combination of below-average P/BV and above-average RoEs is IT

Figure 20: EM sector P/B: Standard deviations from mean



Source: MSCI, UBS

Figure 21: EM sector RoE: Standard deviations from mean




Source: MSCI, UBS

If there is some P/BV vs. RoE value in parts of EM in absolute terms, this seems to disappear when the metric is compared to DM sectors. Since end-2010, EM equities have eroded steadily from a P/BV premium to DM of 18% to a discount of 32% (1.42x v. 2.09x) today (Figure 22), a discount that has kept widening recently, unlike the EM/DM P/E discounts. The P/BV discount to DM is in the lower half of the monthly frequency distribution of this metric since 1995 (Figure 14).


The ratio of EM P/B relative to DM is 0.41 standard deviations below its long-term mean

Figure 22: EM, DM P/B ratios



Source: MSCI, UBS

Figure 23: Distribution of EM P/B relative to DM




Source: MSCI, Datastream, UBS

However, the RoE relative has also been declining against EM (Figures 15-16). Although this EM/DM discount is still sitting at only 4% today (10.4% vs. 10.8%), this compares to a premium of 23% (285bp) as recently as late-2011. So, while the P/BV discount to DM is in the lower half of its frequency distribution, so is the RoE.


The ratio of EM RoE relative to DM is 0.23 standard deviations below its long-term mean

Figure 24: EM, DM RoE



Source: MSCI, UBS

Figure 25: Distribution of EM RoE relative to DM




Source: MSCI, Datastream, UBS

Finally, if we look at P/BV valuations vs. RoEs by sector versus DMs, some clarity does emerge. There are three sectors with above-average relative P/BVs but also above-average RoEs (Figure 18 and Figure 27) – expensive sectors versus DM, but with higher profitability – these are Health Care, Consumer Staples and Utilities.


In the opposite direction, five other sectors – Materials, IT, Telecoms, Industrials and Consumer Discretionary – have P/BV discounts versus DM but also RoE discounts.

Figure 26: EM sectors P/B relative to DM: Standard deviations from 20y mean



Source: MSCI, Datastream, UBS

Figure 27: EM sectors RoE relative to DM: Standard deviations from 20y mean



Source: MSCI, Datastream, UBS

On this basis, the only attractive EM sectors versus DM (below-average P/BVs and above-average RoEs) are Energy (mainly due, in this case, to falling earnings power and Book Values for Energy companies in DM) and Financials (a sector that has been badly hit across global markets in recent months). Utilities also look attractive in that they provide much higher relative RoE for than their relative (expensive) valuations.


We think there is a very good reason the market has not pushed the P/B higher despite high RoEs. It is simply that the market doesn't expect these RoEs to sustain.

Energy and financials are seem to be the only sectors with a combination of average relative (to DM) RoE and below average relative (to DM) PM. Utilities are expensive but their relative RoE difference over DM seems to be higher

Note that these are precisely the sectors with significantly above-average market cap weights in state owned enterprises. According to the annual update of our proprietary SOE database³, we estimate that 58% of the EM Energy index and 43% of EM Financials is in SOEs, versus an average for MSCI GEMs of 27% (Figure 28).

The sectors where RoE is high relative to P/B are ones which have very high SOE representation

Figure 28: SOEs in GEMs: % of Sector Market Cap



Source: IBES, MSCI, UBS estimates

To put it plainly then, we don't find EM cheap at an aggregate or a sector level in absolute or relative terms. Given this backdrop we have been picking our country and sector preferences based on a least-worst basis. In this context we like the EM technology, consumer discretionary industrials and energy relative to materials, consumer staples, telecoms and utilities. By countries we are overweight India, China, Colombia, Russia, Poland and Turkey, and underweight Brazil, South Africa, Malaysia, Thailand, Greece, and Chile.

Sector and country preferences

³ See "GEM SOEs: Underperforming and Underweight", Macro Keys, Geoffrey Dennis, March 29, 2016.

EM FX: If it ain't fixed, keep fixing it

EM currencies have seen significant turbulence in recent years. Stare at a long-term chart of USDBRL, USDTRY or USDZAR for instance, and you'd be forgiven for mistaking the global financial crisis of 2008 for 2013-2015. However following a backtracking Fed, and signs of stabilising growth in China and in oil prices, many clients have put forward the view that this asset class may finally have reached an inflexion point.

We noted in [part 2](#) of this series of notes that the current configuration of economic and financial variables in EM is very different from that seen in previous spells of EM appreciation, that trade balance improvement was likely not be a sufficient condition for currencies to stabilise, and that EM cyclically continues to show few signs of improving competitiveness or improving external demand. Today we aim to take a deeper dive into EM FX valuation from a more structural perspective. In particular we examine:

- The long-term level of EM real effective exchange rates (REERs) relative to the long-term level of EM export growth,
- The evolution of unit labour cost (ULC) based exchange rates in EM, to gain a more accurate assessment of the degree of EM FX movement that has actually accrued in recent years,
- The findings of our fundamental equilibrium exchange rate (FEER) model, which attempts to identify currency over- or under-valuation in the context of the strength of the balance of payments


We look at structural EM valuations using three tools

1) EM real effective exchange rates: Mean reversion aversion

We start by looking at the level of EM REERs as a percentile of their ranges over the last 20 years, a long history that incorporates different EM growth, commodity, and risk cycles. While a few currencies (e.g. the MXN, ZAR, and MYR) have fallen to two-decade lows on this measure, this is far from a universal finding: averaging across the 22 EMs shown below, EM REERs stand at the 41st percentile of their 20-year distribution. When we consider that EM export growth stands at just the 4th percentile of its 20-year distribution, this valuation hardly screams of distress.

Given the export reality, it's hard to talk of distress in EM FX valuations on aggregate

Figure 29: EM REER (levels) vs. export growth (% y/y) – percentile of 20y distributions



Source: Haver, UBS

More importantly, we think it would be misleading to focus purely on the level of EM REERs as a means to identifying valuation in FX. This is because EM REERs are statistically not mean reverting variables, i.e. most EM REERs trend over time, and because price elasticities for EM exports have tended to be much less important than income elasticities in driving EM exports (Figure 30). In today's environment of subdued global income and trade growth, price elasticities are likely to be especially weak: EM REERs are likely to need to do even more heavy lifting than usual to stimulate exports. This makes the threshold for identifying currency undervaluation increasingly demanding.

Price elasticities of EM exports are typically far weaker than income elasticities, meaning currencies have to work very hard in a world of weak global trade

Figure 30: Price vs. income elasticities of EM exports: results from regressing EM export growth (% y/y) on REER changes (% y/y) and G3 GDP growth (% y/y), Q1 2000 - Q4 2015

	REER	G3 GDP growth
Korea	-0.10	3.64
Thailand	-0.13	4.45
Brazil	-0.18	3.83
Mexico	0.12	3.12
South Africa	-0.13	3.12
Turkey	0.06	2.02
Poland	-0.05	3.14
Malaysia	-0.60	4.43
Taiwan	0.41	5.11
Indonesia	-0.30	4.07
Israel	0.34	4.79
Russia	0.03	2.39
Singapore	-0.18	4.06
EM average	-0.05	3.70

Source: Haver, UBS

Note: bolded values denote significance at a 90% confidence level.

2) Measuring FX movements properly: the rise of the ULC-based REER

We have argued in previous research that many investors appear to be overstating the degree of weakness that has actually taken place in EM FX in recent years. This is because most market participants look at CPI-based REERs, while we believe unit labour cost (ULC) based REERs are a more accurate gauge of real EM FX movements. Why do we think this?

CPI is not the relevant inflation rate to help think about external competitiveness in EM, in our view. To the extent that it is heavily influenced by items such as food and fuel prices, given their high share in EM inflation baskets, CPI trends will likely tell us far less about export competitiveness than the growth in unit labour costs i.e. the cost needed to compensate workers for each unit of output produced. This is particularly true in the last few years during which wages have grown considerably faster than CPI in recent years.


We think investors are drawing the wrong conclusions as to how strongly EM FX has actually depreciated, by looking at CPI REERs

At the same time, EM productivity growth has strongly decelerated, exerting additional upside pressure on EM unit labour costs. With EM wages rising strongly and productivity flat-lining, it's little wonder that exchange rates have needed to depreciate strongly for EM competitiveness just to stand still.

ULC data is difficult to extract for several EMs, but on the next page we present our estimates of the ULC based REER for Mexico, Brazil, Chile, Turkey, South Africa, and Korea. We have included the CPI-based REER and the local terms of trade (for commodity exporters) and export growth (for commodity importers) for reference.


We're partial to ULC-based REERs over CPI based REERS. See the next page for our estimates for 6 key EM countries

Figure 31: BRL CPI- and ULC-based REER vs. terms of trade




Source: Haver, UBS

Figure 32: MXN CPI- and ULC-based REER vs. terms of trade




Source: Haver, UBS

Figure 33: ZAR CPI- and ULC-based REER vs. terms of trade




Source: Haver, UBS

Figure 34: TRY CPI- and ULC-based REER vs. export growth




Source: Haver, UBS

Figure 35: KRW CPI- and ULC-based REER vs. export growth



Source: Haver, UBS

Figure 36: CLP CPI- and ULC-based REER vs. terms of trade



Source: Haver, UBS

From the charts above we can make two key points about EM FX valuation:

First, ULC-based REERs have risen far more strongly in recent years than CPI-based REERs. Indeed, with the exception of the ZAR, **most of the currencies shown in the charts above have depreciated only very slightly since 2011**, despite many of them weakening as much as 30-50% against the dollar in nominal terms. We suspect the same would be true for other key markets such as the INR and IDR. This limited depreciation in ULC-based REERs likely helps explain the very limited responsiveness of EM exports and export shares in these countries to FX depreciation.

Second, when ULC REERs are overlaid against the deterioration in these countries' terms of trade (for commodity producers) or export growth (for commodity importers), the **weakness in EM exchange rates generally does not look excessive**. The last time ULC-based REERs were at these levels, terms of trade and export growth were far stronger than is the case today. This suggests further trade-weighted depreciation for these currencies may be in store.

3) What does FEER tell us about the health of EM balance of payments?

REER based valuation models are a useful measurement tool, but to the extent that they begin and end in currency movements, they tell us little about the actual state of EM fundamentals. To help with this, we draw on our fundamental equilibrium exchange rate (FEER) model⁴. FEER is based on the simple premise that the proof of currency over/undervaluation lies in the strength of the balance of payments, in particular whether the predicted current account looks sustainable over the medium term, without needing to on potentially fickle portfolio and 'other investment' inflows. In contrast to mean-reverting REER valuation models, FEER has the important advantage of being able to adjust for weakening income elasticities of EM exports better than REER, and has had a stronger track record in recent years.


While EM current account positions have improved strongly since late 2013, this has been entirely due to weaker domestic demand and commodity prices. This has had the result of pushing EM growth weaker, both in absolute terms and relative to DM, in turn pressuring capital account outflows (Figure 37). In fact, capital account flows to EM are now running at the weakest levels in at least a decade – and worse than during the 2008 crisis – compromising EM FX even as current accounts improve. The good news is that some of this reflects increased outward investment from EM that can be repatriated back during times of stress. The bad news is that this may count for little in today's weak growth, moderate volatility environment.

FEER can tell us more about the absolute valuation of EM currencies than PPP based valuation models

Though current account positions have improved across most of EM, the reverse is true for growth and capital accounts

⁴ For details on our FEER model, please refer to [EM Navigator: Where is fair value in EM currencies now?](#)

Figure 37: EM capital account flows have traditionally been well correlated with EM-DM growth spreads




Source: Haver, UBS

Note: EM capital flows shown here is GDP weighted average of 22 EM countries.

Our FEER model thus shows that several EMs continue to screen as fundamentally overvalued – in particular the BRL, ZAR, IDR, COP and PEN (Figure 38). Unfortunately these markets comprise a heavy share of the local currency debt (GBI-EM) benchmark (Figure 39). While valuation looks fair to cheap for much of MSCI EM, especially for markets in Asia and CEE, weak trade, low inflation, and a depreciating CNY mean that investors should be alert to risk that strengthening/stability in these currencies could well play out more in real terms (inflation) than in investable nominal appreciation.


Much of the identified undervaluation in MSCI EM has played out in recent years through real, rather than nominal appreciation

Figure 38: UBS FEER results: % chg in REER required to achieve macro adjustment



Source: Haver, UBS

Figure 39: Average EM REER undervaluation, %




Source: Haver, UBS

EM credit: Balance sheet pressures to persist even if commodities stabilise

The path of spreads in the first quarter of this year has been more winding than a rollercoaster, but we actually find ourselves close to unchanged from levels at the start of the year. Stability in spreads has been good enough to provide decent returns in this asset class, thanks to the coupon, but more importantly to the move lower in rates (Figure 40).

Spreads have detracted from returns for 3 years but have been net neutral year to date

Figure 40: EM sovereign credit spreads : Total return attribution



Source: Datastream, UBS

For our purposes here we regard coupon as a given, take a neutral view on US rates, and focus really on what drives spreads, and where we should be headed from here.


Modelling EM credit spreads

We base our trading fair value for EM spreads on a) the state of EM macro balance sheets, b) commodity prices and c) global risk appetite.

In 2016 EM income statements ought not to see the degree of 'incremental' deterioration they have done over the last 5 years. However, the accumulated impact of lack of growth, which even today is really only flat-lining at a weak level, has already infected EM's stock variables, we believe. A state of drift in growth is no longer net neutral for EM – current low growth will drive a passive worsening of EM's credit risk.

A state of drift at current low growth levels is no longer net neutral; it will passively drive credit risk higher

Figure 41: UBS EM macro balance sheet risk score




Source: Haver, UBS

We have conceptualised EM macro risk in our macro balance sheet risk score which is an aggregation of leverage risk, external risk, fiscal risk and supply side/institutional risk⁵. This index has given back the gains of the last 10 years, which is the time over which the bulk of fixed income investment has come in. (For greater details see [Theme #1: EM enters a new, dangerous phase.](#))

Our macro balance score conceptualises 'fundamentals' in our fair value model for spreads

Figure 42: Actual vs. fitted EMBI global diversified spreads



Source: Bloomberg, Datastream, UBS

Our measure of commodity prices excludes agricultural commodities and focuses instead on oil (75%) and metals (25%) as these constitute the revenue streams of EM issuers. There is some correlation between the macro balance sheet score and commodity price trends, but this doesn't change the overall results at all⁶. We enter commodity prices in log form in our model to aid ease of interpretation.

⁵ 12 risk variables that constitute the sub-indices in our macro balance sheet risk scores are: credit to GDP level (deviation from per capita income forecasted level), change in credit to GDP, current account, external debt to GDP, short term external debt to reserves, FDI, net international investment assets, the proportion of external debt denominated in foreign currencies, fiscal balance, public debt, WB governance indicators and a proxy for the slope of the Phillips curve.

⁶ We can also overcome this multicollinearity by replacing the macro balance sheet (MBS) with the residual of the regression of MBS scores on commodity prices – a commodity free balance sheet risk score. We've confirmed that this innovation doesn't change the overall picture at all, and so we've presented the original version, which is more straightforward to interpret.

Regular readers would be familiar with our risk premium proxy, which is the first principal component of volatility across developed market assets⁷. This muddies the pure fundamentals with a 'trading' component but is nonetheless a very important element of the fair value model in a world where central banks are trying to control not only the risk free rate, but also the risk premium.

Model forecasts

We find that EM sovereign credit spreads (we model EMBI global diversified spreads) are in a co-integrating relationship with our explanatory variables, which allows us to use the levels regression as a proxy of the long-term relationship. Here is the model equation⁸

$$\text{EMBI} = -272.8 - 91.5 * \log(\text{Commodity}) + 65.67 * \text{global risk} + 60.19 * \text{balance sheet risk score}$$

(2.27) (-6.84) (10.6) (10.15) R sq 82%

Each one point of score deterioration in our macro balance sheet risk index leads predicts a widening of spreads by 60 bps, a 10% drop in commodities is consistent with a 10 bps widening while a deterioration in global risk appetite by one standard deviation also drives spreads wider by about 65 bps.

The analysis tells us that at the present, spreads are about 30 bps too tight. However, this is the less interesting part of the result. The equation allows us to play with future scenarios, which is important given we believe that EM fundamentals such as private and public leverage ratios and possibly external debt will continue to drift wider if nominal growth doesn't improve.

We expect EMBI GD spreads to drift wider towards 480 bps year end. The current level of growth is consistent with 0.3-0.5 point widening per annum in our macro balance sheet risk. With this drift, and assuming a) that global risk appetite is positioned right at the median of its long-term distribution, and b) commodity prices stay largely unchanged, we see (sovereign) spreads widening by 50-70 bps from current levels. The table below outlines this base case, and other 'high likelihood' alternative case scenarios

Spreads presently look 30 bps too tight

We expect them to widen by 50-70 bps from current levels by year end

Figure 43: EMBI GD Spreads under different scenarios

		Macro balance sheet risk score		
		9.8	10.4	11.0
Commodity price scenarios	20% down	423	465	503
	No Change	399	440	478
	20% up	376	417	460

Source: Bloomberg, Datastream, UBS

It is important to remind readers here that this model is a linear model, an abstraction of reality which tends to become less accurate the wider spreads go. That is because it doesn't incorporate the non linearities that emanate from liquidity risk which rise sharply in times of stress. As a result of this we would interpret the numbers above as best case scenarios, should our assumptions come to pass.

As spreads go higher, the risk of illiquidity driven non-linear moves rises


⁷ Our DM risk premium metric is calculated as the first principal component of US and EU HY spreads, US and German equity market vol, USDJPY, AUDJPY and EURUSD vol, US/EU TED spreads and US Treasury options volatility.

⁸ Numbers in brackets denotes T-statistic.

Corporates likely to underperform sovereign


As we've noted previously, in the medium to long term EM has to grapple with the issue of quasi sovereign corporates infecting public debt ratios in EM sovereigns (see [Theme #6: Simmering trouble – Mapping the path of EM pain](#)). This will first weigh on EM financial spreads though, and along with weakness in commodity prices (corporate spreads display higher sensitivity to commodity prices and global risk appetite than do sovereign) this should mean that corporates underperform sovereigns.

Figure 44: EM sovereign and corporate spreads



Source: Bloomberg, UBS

Figure 45: Year to date performance of spreads by rating




Source: Datastream, Bloomberg, UBS

Another variable that will impact the performance of corporate spreads is the higher debt redemption profile (Figure 46) in the face of a less euphoric primary market issuance (Figure 47). Clearly, the generosity from global central banks has the potential to renew animal spirits in EM, but thus far this year the amounts issued have been miniscule compared to earlier years. As we've noted in the past (See [Theme #6: Simmering trouble – Mapping the path of EM pain](#)) nearly 30% of issuance in EM has likely been directed to rolling over maturing debt. As this source becomes less reliable the pressure on corporate spreads could increase. We are looking for 75-100 bps widening in corporate credit from current levels.

In addition to the drift wider in sovereigns, corporate spreads are likely to be pressured by higher redemption pressures in the face of a less generous primary market


Figure 46: EM USD debt refinancing schedule



Source: Bloomberg, UBS estimates

Note: Total EM data here is summed from 38 economies.

Figure 47: Jan - March primary issuance in EM



Source: Bloomberg, UBS

Local rates: Optically appealing, but beware rising credit risk


At the outset we should point out there is no discussion on EM local currency bonds without one on EM FX. The experience of the past 10 years shows that FX is typically the most important swing variable for returns in this asset class, with USD-based investors typically never earning positive total returns in years when spot depreciates. While transitory FX depreciation can be hedged away, it is prohibitively costly to do so when FX weakness is persistent. We estimate that GBI-EM weighted 10yr yields fall from 7.0% to just 1.8% annualised net of FX hedging costs. Our cautious views on EM currencies have been outlined in the previous chapter, and in this section we focus on pure rates valuations.

The first point to make is that there is massive variation across EM yields. Yields in North Asia, Chile, Israel, and the CEE today trade close to the lowest levels seen since 2010, while those in South Africa, Brazil, and Colombia are close to their highest. On aggregate, though, benchmark (GBI) EM 10y yields are today trading slap bang in the middle of their ranges over this period (Figure 48).

Currencies a key driver of total returns in EM local currency debt. In this chapter we focus purely on rates valuations


EM yields characterised by wide dispersion

Figure 48: 10y yields in EM: percentiles since 2010



Source: Haver, Bloomberg, UBS

Figure 49: 10y bond yields in EM – ranges since 2010



Source: Haver, Bloomberg, UBS


Note: Values above individual country bars denote percentile of range since 2010.

Figure 50: Standard deviation of EM bond yields



Source: Haver, Bloomberg, UBS

Figure 51: EM vs. DM 10y yields



Source: Haver, Bloomberg, UBS

Note: DM here is a 60-40 average of US and German bond yields. GBI EM series uses constant, not rolling, country weights.

Arguably, in the context of developed world yields moving significantly lower since 2010, this makes EM rates look very competitive optically. Indeed, EM yields relative to the G2 stand at the 95th percentile of their range since 2010 (Figure 49).

EM nominal yields trading at historically wide levels vs. DM. Is that good enough?

The above considerations though have only looked at nominal yields, and clearly this is a very simplistic and partial way of thinking about bond market valuations. While in a low volatility and rising commodity environment nominal considerations may suffice, in current market conditions and over longer time horizons we prefer to adjust nominal yields for two factors: 1) inflation and 2) credit risk. Indeed, while we observed earlier that bond yields in markets such as South Africa, Brazil, Colombia, and Malaysia are quite high relative to their post-2010 ranges, the same can also be said for inflation and particularly credit risk in these economies.

First, we proxy inflation expectations across EM markets using a rolling 2-year average of CPI growth⁹. In the absence of reliable inflation linker data and in view of the generally adaptive nature of inflation expectations in EM, we think this is a reasonable if imperfect proxy to use. Second, we use 5y CDS spreads to strip out implied credit risk¹⁰. Particularly after adjusting for the latter, the valuation story for EM changes more significantly. While we find that while EM still offers a clear pick-up over DM rates, the differential is about 45th percentile of its range since 2010 – taking us back to a "middle of the pack" valuation conclusion. It seems worth noting that this valuation is quite different from 2011, H1 2012, and H1 2014, when EM bond yields enjoyed strong compression.

We prefer to look at EM rates valuations net of inflation and credit risk


Overall, while do see the appeal of EM rates in a world of low DM yields and where most EM central banks are comfortable accommodating weaker currencies in pursuit of growth, we believe EM investors will need to be highly selective. We believe rates in India, Indonesia, Korea, Hungary, Mexico, and Brazil offer opportunities though we would advocate FX hedging in each of these cases.

We favour rates over FX in India, Indonesia, Korea, Hungary, Mexico, and Brazil

⁹ While 2y rolling CPI is today likely punitively high as a proxy for inflation expectations in markets such as Brazil, Indonesia, and Russia, we are not convinced that this is the case for the benchmark as a whole. The opposite is likely true for South Africa, Poland, and Malaysia for instance.

¹⁰ Many investors have asked us why we use 5y CDS – a measure of protection in hard currency debt – to proxy credit risks for local debt investors. We agree this may be conservative but over time we have found a close connection between CDS spreads and term premia in local bond markets in EM. Second, using FX hedging costs to deflate risks faced by local debt investors would be excessively punitive. CDS spreads seem a reasonable compromise.


Figure 52: EM and DM: 10y yields net of inflation and credit risk



Source: Haver, Bloomberg, UBS estimates

Note: for EM, chart shows 10y bond yield – 2y rolling CPI – 5y CDS. EM is weighted using constant GBI weights. For DM, chart shows 10y real (linker) yield – 5y CDS. G2 uses 60% US, 40% Germany weight.

Figure 53: EM minus DM: 10y yields net of inflation and credit risk



Source: Haver, Bloomberg, UBS estimates

Note: for EM, chart shows 10y bond yield – 2y rolling CPI – 5y CDS. EM is weighted using constant GBI weights. For DM, chart shows 10y real (linker) yield – 5y CDS. G2 uses 60% US, 40% Germany weight.

Figure 54: EM Tactical Trade Monitor

EM F/FX Trades						
	P&L Units	Date of entry	Entry level	Date of closing	Current level	P&L
Long CNY Short INR position expressed through 3m NDFs						
Short USDCNY	%	12-Jan-16	6.56		6.47	3.5%
Long USDINR	%	12-Jan-16	66.75		66.47	-1.9%
Long Indian Rupee vs South African Rand						
Short ZARINR	%	1-Dec-14	5.59	12-Dec-15	3.99	28.0%
Receive Israel 5y5y against USD						
Rec ILS 5y5y	bp	26-Oct-15	3.06		2.43	61
Pay USD 5y5y	bp	26-Oct-15	2.69		2.06	-63
Long Korean Won vs Indonesian Rupiah						
Long USDIDR	%	14-Mar-16	13090		13135	-0.4%
Short USDKRW	%	14-Mar-16	1190		1154	3.2%
Source: UBS, Bloomberg, Datastream						7-Apr-16
Past performance is not an indication of future results						
Year to date, the EMBI-GD benchmark (hard currency debt) has returned 5.2%. The local currency debt GBI-EM benchmark has returned 9.3% (In USD terms)						
Final PnL (in bp) includes carry/roll						

Figure 55: EM Structural Trade Monitor

	P&L Units	Date of entry	Entry level	Date of closing	Current level	P&L
Long DM Financials vs EM Financials						
Long DM Financials	%	17-Nov-15	159.63		145.20	-9.0%
Short EM Financials	%	17-Nov-15	441.53		420.87	4.7%
Long USD vs Asian currency basket of TWD, PHP, SGD and THB						
Long USDTHB	%	17-Nov-15	36.00		35.20	-1.3%
Long USDPHP	%	17-Nov-15	47.19		46.14	-1.3%
Long USDTWD	%	17-Nov-15	32.84		32.38	-1.5%
Long USDSGD	%	17-Nov-15	1.4241		1.3524	-4.7%
Overweight Taiwan Equities vs Malaysia (FX-hedged)						
Long Taiwan Equities	%	17-Nov-15	8,419		8,490	0.8%
Short Malaysia Equities	%	17-Nov-15	1,662		1,724	-3.8%
Long 5yr CNY onshore government bond, Short Australian Dollar vs Chinese Renminbi						
Long 5Yr CNY onshore government bond	%	17-Nov-15	3.100		2.530	2.6%
Short AUDCNY	%	17-Nov-15	4.535		4.907	-10.0%
Long India fixed income vs Turkey (FX-unhedged)						
Long Jul-24 IGB's	%	17-Nov-15	7.67		7.66	2.8%
Short Jul-24 TurkGB's	%	17-Nov-15	9.72		9.69	-3.7%
Long INRTRY	%	17-Nov-15	0.0435		0.0428	-1.6%
Short USD/CLP, long USD/ZAR						
Short USD/CLP	%	17-Nov-15	711.37		678.76	3.2%
Long USD/ZAR	%	17-Nov-15	14.27		15.21	9.3%
Buy 3y NTNf's vs equities in Brazil						
Receive Jan'19s	bps	17-Nov-15	15.76		13.92	401
Short Ibov equity index	%	17-Nov-15	47,248		48,096	-1.8%
Receive MXN 1y1y rates. Long USD/MXN						
Receive MXN 1y1y	bps	17-Nov-15	4.8		4.9	-5.0
Long USDMXN	%	17-Nov-15	16.7		17.8	7.4%
Long US IG against EM low-beta credit						
Long USD IG	bps	17-Nov-15	83.39		75.98	18.77
Short EM low-beta credit	bps	17-Nov-15	117.28		123.54	-5.27
Sell Brazil 2y CDS protection						
Short Brazil 2y CDS	bps	17-Nov-15	317.48		156.08	267.80

Source: UBS, Bloomberg, Datastream

Market Pricing as of 1030 GMT on

7-Apr-16

Past performance is not an indication of future results

Since 17-Nov-15, the EMBI-GD benchmark (hard currency debt) has returned 4.0%. The local currency debt GBI-EM benchmark has returned 6.4% (In USD terms)

Final PnL (in bp) includes carry/roll

Valuation Method and Risk Statement

Risks of multi-asset investing include but are not limited to market risk, credit risk, interest rate risk, and foreign exchange risk. Correlations of returns among different asset classes may deviate from historical patterns. Geopolitical events and policy shocks pose risks that can reduce asset returns. Valuations may be adversely affected during times of high market volatility, thin liquidity, and economic dislocation.

Required Disclosures

This report has been prepared by UBS Limited, an affiliate of UBS AG. UBS AG, its subsidiaries, branches and affiliates are referred to herein as UBS.

For information on the ways in which UBS manages conflicts and maintains independence of its research product; historical performance information; and certain additional disclosures concerning UBS research recommendations, please visit www.ubs.com/disclosures. The figures contained in performance charts refer to the past; past performance is not a reliable indicator of future results. Additional information will be made available upon request. UBS Securities Co. Limited is licensed to conduct securities investment consultancy businesses by the China Securities Regulatory Commission. UBS acts or may act as principal in the debt securities (or in related derivatives) that may be the subject of this report.

Analyst Certification: Each research analyst primarily responsible for the content of this research report, in whole or in part, certifies that with respect to each security or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about those securities or issuers and were prepared in an independent manner, including with respect to UBS, and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by that research analyst in the research report.

Company Disclosures

Issuer Name

Brazil^{7, 22}

Chile⁷

China (Peoples Republic of)^{4, 5, 7}

Colombia

Government of Indonesia

Greece⁷

Hungary

India (Republic Of)⁷

Korea (Republic of)

Malaysia

Mexico²²

Poland⁷

Russia^{4, 7}

South Africa (Republic of)⁷

Thailand (Kingdom of)

Turkey

4. Within the past 12 months, UBS AG, its affiliates or subsidiaries has received compensation for investment banking services from this company/entity or one of its affiliates.
5. UBS AG, its affiliates or subsidiaries expect to receive or intend to seek compensation for investment banking services from this company/entity within the next three months.
7. Within the past 12 months, UBS Securities LLC and/or its affiliates have received compensation for products and services other than investment banking services from this company/entity.
22. UBS AG, its affiliates or subsidiaries held other significant financial interests in this company/entity as of last month's end (or the prior month's end if this report is dated less than 10 working days after the most recent month's end).

Unless otherwise indicated, please refer to the Valuation and Risk sections within the body of this report. For a complete set of disclosure statements associated with the companies discussed in this report, including information on valuation and risk, please contact UBS Securities LLC, 1285 Avenue of Americas, New York, NY 10019, USA, Attention: Investment Research.

Global Disclaimer

This document has been prepared by UBS Limited, an affiliate of UBS AG. UBS AG, its subsidiaries, branches and affiliates are referred to herein as UBS.

Global Research is provided to our clients through UBS Neo, the UBS Client Portal and UBS.com (each a "System"). It may also be made available through third party vendors and distributed by UBS and/or third parties via e-mail or alternative electronic means. The level and types of services provided by Global Research to a client may vary depending upon various factors such as a client's individual preferences as to the frequency and manner of receiving communications, a client's risk profile and investment focus and perspective (e.g. market wide, sector specific, long-term, short-term, etc.), the size and scope of the overall client relationship with UBS and legal and regulatory constraints.

When you receive Global Research through a System, your access and/or use of such Global Research is subject to this Global Research Disclaimer and to the terms of use governing the applicable System.

When you receive Global Research via a third party vendor, e-mail or other electronic means, your use shall be subject to this Global Research Disclaimer and to UBS's Terms of Use/Disclaimer (<http://www.ubs.com/global/en/legalinfo2/disclaimer.html>). By accessing and/or using Global Research in this manner, you are indicating that you have read and agree to be bound by our Terms of Use/Disclaimer. In addition, you consent to UBS processing your personal data and using cookies in accordance with our Privacy Statement (<http://www.ubs.com/global/en/legalinfo2/privacy.html>) and cookie notice (<http://www.ubs.com/global/en/homepage/cookies/cookie-management.html>).

If you receive Global Research, whether through a System or by any other means, you agree that you shall not copy, revise, amend, create a derivative work, transfer to any third party, or in any way commercially exploit any UBS research provided via Global Research or otherwise, and that you shall not extract data from any research or estimates provided to you via Global Research or otherwise, without the prior written consent of UBS.

For access to all available Global Research on UBS Neo and the Client Portal, please contact your UBS sales representative.

This document is for distribution only as may be permitted by law. It is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or would subject UBS to any registration or licensing requirement within such jurisdiction. It is published solely for information purposes; it is not an advertisement nor is it a solicitation or an offer to buy or sell any financial instruments or to participate in any particular trading strategy. No representation or warranty, either expressed or implied, is provided in relation to the accuracy, completeness or reliability of the information contained in this document ('the Information'), except with respect to Information concerning UBS. The Information is not intended to be a complete statement or summary of the securities, markets or developments referred to in the document. UBS does not undertake to update or keep current the Information. Any opinions expressed in this document may change without notice and may differ or be contrary to opinions expressed by other business areas or groups of UBS. Any statements contained in this report attributed to a third party represent UBS's interpretation of the data, information and/or opinions provided by that third party either publicly or through a subscription service, and such use and interpretation have not been reviewed by the third party.

Nothing in this document constitutes a representation that any investment strategy or recommendation is suitable or appropriate to an investor's individual circumstances or otherwise constitutes a personal recommendation. Investments involve risks, and investors should exercise prudence and their own judgement in making their investment decisions. The financial instruments described in the document may not be eligible for sale in all jurisdictions or to certain categories of investors. Options, derivative products and futures are not suitable for all investors, and trading in these instruments is considered risky. Mortgage and asset-backed securities may involve a high degree of risk and may be highly volatile in response to fluctuations in interest rates or other market conditions. Foreign currency rates of exchange may adversely affect the value, price or income of any security or related instrument referred to in the document. For investment advice, trade execution or other enquiries, clients should contact their local sales representative.

The value of any investment or income may go down as well as up, and investors may not get back the full (or any) amount invested. Past performance is not necessarily a guide to future performance. Neither UBS nor any of its directors, employees or agents accepts any liability for any loss (including investment loss) or damage arising out of the use of all or any of the Information.

Any prices stated in this document are for information purposes only and do not represent valuations for individual securities or other financial instruments. There is no representation that any transaction can or could have been effected at those prices, and any prices do not necessarily reflect UBS's internal books and records or theoretical model-based valuations and may be based on certain assumptions. Different assumptions by UBS or any other source may yield substantially different results.

This document and the Information are produced by UBS as part of its research function and are provided to you solely for general background information. UBS has no regard to the specific investment objectives, financial situation or particular needs of any specific recipient. In no circumstances may this document or any of the Information be used for any of the following purposes:

- (i) valuation or accounting purposes;
- (ii) to determine the amounts due or payable, the price or the value of any financial instrument or financial contract; or
- (iii) to measure the performance of any financial instrument.

By receiving this document and the Information you will be deemed to represent and warrant to UBS that you will not use this document or any of the Information for any of the above purposes or otherwise rely upon this document or any of the Information.

Research will initiate, update and cease coverage solely at the discretion of UBS Investment Bank Research Management. The analysis contained in this document is based on numerous assumptions. Different assumptions could result in materially different results. The analyst(s) responsible for the preparation of this document may interact with trading desk personnel, sales personnel and other parties for the purpose of gathering, applying and interpreting market information. UBS relies on information barriers to control the flow of information contained in one or more areas within UBS into other areas, units, groups or affiliates of UBS. The compensation of the analyst who prepared this document is determined exclusively by research management and senior management (not including investment banking). Analyst compensation is not based on investment banking revenues; however, compensation may relate to the revenues of UBS Investment Bank as a whole, of which investment banking, sales and trading are a part.

For financial instruments admitted to trading on an EU regulated market: UBS AG, its affiliates or subsidiaries (excluding UBS Securities LLC) acts as a market maker or liquidity provider (in accordance with the interpretation of these terms in the UK) in the financial instruments of the issuer save that where the activity of liquidity provider is carried out in accordance with the definition given to it by the laws and regulations of any other EU jurisdictions, such information is separately disclosed in this document. For financial instruments admitted to trading on a non-EU regulated market: UBS may act as a market maker save that where this activity is carried out in the US in accordance with the definition given to it by the relevant laws and regulations, such activity will be specifically disclosed in this document. UBS may have issued a warrant the value of which is based on one or more of the financial instruments referred to in the document. UBS and its affiliates and employees may have long or short positions, trade as principal and buy and sell in instruments or derivatives identified herein; such transactions or positions may be inconsistent with the opinions expressed in this document.

United Kingdom and the rest of Europe: Except as otherwise specified herein, this material is distributed by UBS Limited to persons who are eligible counterparties or professional clients. UBS Limited is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority. **France:** Prepared by UBS Limited and distributed by UBS Limited and UBS Securities France S.A. UBS Securities France S.A. is regulated by the ACPR (Autorité de Contrôle Prudentiel et de Résolution) and the Autorité des Marchés Financiers (AMF). Where an analyst of UBS Securities France S.A. has contributed to this document, the document is also deemed to have been prepared by UBS Securities France S.A. **Germany:** Prepared by UBS Limited and distributed by UBS Limited and UBS Deutschland AG. UBS Deutschland AG is regulated by the Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin). **Spain:** Prepared by UBS Limited and distributed by UBS Limited and UBS Securities España SV, SA. UBS Securities España SV, SA is regulated by the Comisión Nacional del Mercado de Valores (CNMV). **Turkey:** Distributed by UBS Limited. No information in this document is provided for the purpose of offering, marketing and sale by any means of any capital market instruments and services in the Republic of Turkey. Therefore, this document may not be considered as an offer made or to be made to residents of the Republic of Turkey. UBS AG is not licensed by the Turkish Capital Market Board under the provisions of the Capital Market Law (Law No. 6362). Accordingly, neither this document nor any other offering material related to the instruments/services may be utilized in connection with providing any capital market services to persons within the Republic of Turkey without the prior approval of the Capital Market Board. However, according to article 15 (d) (ii) of the Decree No. 32, there is no restriction on the purchase or sale of the securities abroad by residents of the Republic of Turkey. **Poland:** Distributed by UBS Limited (spółka z ograniczoną odpowiedzialnością) Oddział w Polsce regulated by the Polish Financial Supervision Authority. Where an analyst of UBS Limited (spółka z ograniczoną odpowiedzialnością) Oddział w Polsce has contributed to this

document, the document is also deemed to have been prepared by UBS Limited (spółka z ograniczoną odpowiedzialnością) Oddział w Polsce. **Russia:** Prepared and distributed by UBS Bank (OOO). **Switzerland:** Distributed by UBS AG to persons who are institutional investors only. UBS AG is regulated by the Swiss Financial Market Supervisory Authority (FINMA). **Italy:** Prepared by UBS Limited and distributed by UBS Limited and UBS Italia Sim S.p.A. UBS Italia Sim S.p.A. is regulated by the Bank of Italy and by the Commissione Nazionale per le Società e la Borsa (CONSOB). Where an analyst of UBS Italia Sim S.p.A. has contributed to this document, the document is also deemed to have been prepared by UBS Italia Sim S.p.A. **South Africa:** Distributed by UBS South Africa (Pty) Limited (Registration No. 1995/011140/07), an authorised user of the JSE and an authorised Financial Services Provider (FSP 7328). **Israel:** This material is distributed by UBS Limited. UBS Limited is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority. UBS Securities Israel Ltd is a licensed Investment Marketer that is supervised by the Israel Securities Authority (ISA). UBS Limited and its affiliates incorporated outside Israel are not licensed under the Israeli Advisory Law. UBS Limited is not covered by insurance as required from a licensee under the Israeli Advisory Law. UBS may engage among others in issuance of Financial Assets or in distribution of Financial Assets of other issuers for fees or other benefits. UBS Limited and its affiliates may prefer various Financial Assets to which they have or may have Affiliation (as such term is defined under the Israeli Advisory Law). Nothing in this Material should be considered as investment advice under the Israeli Advisory Law. This Material is being issued only to and/or is directed only at persons who are Eligible Clients within the meaning of the Israeli Advisory Law, and this material must not be relied on or acted upon by any other persons. **Saudi Arabia:** This document has been issued by UBS AG (and/or any of its subsidiaries, branches or affiliates), a public company limited by shares, incorporated in Switzerland with its registered offices at Aeschenvorstadt 1, CH-4051 Basel and Bahnhofstrasse 45, CH-8001 Zurich. This publication has been approved by UBS Saudi Arabia (a subsidiary of UBS AG), a Saudi closed joint stock company incorporated in the Kingdom of Saudi Arabia under commercial register number 1010257812 having its registered office at Tatweer Towers, P.O. Box 75724, Riyadh 11588, Kingdom of Saudi Arabia. UBS Saudi Arabia is authorized and regulated by the Capital Market Authority to conduct securities business under license number 08113-37. **Dubai:** The information distributed by UBS AG Dubai Branch is intended for Professional Clients only and is not for further distribution within the United Arab Emirates. **United States:** Distributed to US persons by either UBS Securities LLC or by UBS Financial Services Inc., subsidiaries of UBS AG; or by a group, subsidiary or affiliate of UBS AG that is not registered as a US broker-dealer (a 'non-US affiliate') to major US institutional investors only. UBS Securities LLC or UBS Financial Services Inc. accepts responsibility for the content of a document prepared by another non-US affiliate when distributed to US persons by UBS Securities LLC or UBS Financial Services Inc. All transactions by a US person in the securities mentioned in this document must be effected through UBS Securities LLC or UBS Financial Services Inc., and not through a non-US affiliate. UBS Securities LLC is not acting as a municipal advisor to any municipal entity or obligated person within the meaning of Section 15B of the Securities Exchange Act (the "Municipal Advisor Rule"), and the opinions or views contained herein are not intended to be, and do not constitute, advice within the meaning of the Municipal Advisor Rule. **Canada:** Distributed by UBS Securities Canada Inc., a registered investment dealer in Canada and a Member-Canadian Investor Protection Fund, or by another affiliate of UBS AG that is registered to conduct business in Canada or is otherwise exempt from registration. **Brazil:** Except as otherwise specified herein, this material is prepared by UBS Brasil CCTVM S.A. to persons who are eligible investors residing in Brazil, which are considered to be: (i) financial institutions, (ii) insurance firms and investment capital companies, (iii) supplementary pension entities, (iv) entities that hold financial investments higher than R\$300,000.00 and that confirm the status of qualified investors in written, (v) investment funds, (vi) securities portfolio managers and securities consultants duly authorized by Comissão de Valores Mobiliários (CVM), regarding their own investments, and (vii) social security systems created by the Federal Government, States, and Municipalities. **Hong Kong:** Distributed by UBS Securities Asia Limited and/or UBS AG, Hong Kong Branch. **Singapore:** Distributed by UBS Securities Pte. Ltd. [MCI (P) 018/09/2015 and Co. Reg. No.: 198500648C] or UBS AG, Singapore Branch. Please contact UBS Securities Pte. Ltd., an exempt financial adviser under the Singapore Financial Advisers Act (Cap. 110); or UBS AG, Singapore Branch, an exempt financial adviser under the Singapore Financial Advisers Act (Cap. 110) and a wholesale bank licensed under the Singapore Banking Act (Cap. 19) regulated by the Monetary Authority of Singapore, in respect of any matters arising from, or in connection with, the analysis or document. The recipients of this document represent and warrant that they are accredited and institutional investors as defined in the Securities and Futures Act (Cap. 289). **Japan:** Distributed by UBS Securities Japan Co., Ltd. to professional investors (except as otherwise permitted). Where this document has been prepared by UBS Securities Japan Co., Ltd., UBS Securities Japan Co., Ltd. is the author, publisher and distributor of the document. Distributed by UBS AG, Tokyo Branch to Professional Investors (except as otherwise permitted) in relation to foreign exchange and other banking businesses when relevant. **Australia:** Clients of UBS AG: Distributed by UBS AG (Holder of Australian Financial Services License No. 231087). Clients of UBS Securities Australia Ltd: Distributed by UBS Securities Australia Ltd (Holder of Australian Financial Services License No. 231098). Clients of UBS Wealth Management Australia Ltd: Distributed by UBS Wealth Management Australia Ltd (Holder of Australian Financial Services License No. 231127). This Document contains general information and/or general advice only and does not constitute personal financial product advice. As such, the Information in this document has been prepared without taking into account any investor's objectives, financial situation or needs, and investors should, before acting on the Information, consider the appropriateness of the Information, having regard to their objectives, financial situation and needs. If the Information contained in this document relates to the acquisition, or potential acquisition of a particular financial product by a 'Retail' client as defined by section 761G of the Corporations Act 2001 where a Product Disclosure Statement would be required, the retail client should obtain and consider the Product Disclosure Statement relating to the product before making any decision about whether to acquire the product. The UBS Securities Australia Limited Financial Services Guide is available at: www.ubs.com/ecs-research-fsg. **New Zealand:** Distributed by UBS New Zealand Ltd. The information and recommendations in this publication are provided for general information purposes only. To the extent that any such information or recommendations constitute financial advice, they do not take into account any person's particular financial situation or goals. We recommend that recipients seek advice specific to their circumstances from their financial advisor. **Korea:** Distributed in Korea by UBS Securities Pte. Ltd., Seoul Branch. This document may have been edited or contributed to from time to time by affiliates of UBS Securities Pte. Ltd., Seoul Branch. **Malaysia:** This material is authorized to be distributed in Malaysia by UBS Securities Malaysia Sdn. Bhd (Capital Markets Services License No.: CMSL/A0063/2007). This material is intended for professional/institutional clients only and not for distribution to any retail clients. **India:** Prepared by UBS Securities India Private Ltd. (Corporate Identity Number U67120MH1996PTC097299) 2/F, 2 North Avenue, Maker Maxity, Bandra Kurla Complex, Bandra (East), Mumbai (India) 400051. Phone: +912261556000. It provides brokerage services bearing SEBI Registration Numbers: NSE (Capital Market Segment): INB230951431, NSE (F&O Segment) INF230951431, NSE (Currency Derivatives Segment) INE230951431, BSE (Capital Market Segment) INB010951437; merchant banking services bearing SEBI Registration Number: INM000010809 and Research Analyst services bearing SEBI Registration Number: INH000001204. UBS AG, its affiliates or subsidiaries may have debt holdings or positions in the subject Indian company/companies. Within the past 12 months, UBS AG, its affiliates or subsidiaries may have received compensation for non-investment banking securities-related services and/or non-securities services from the subject Indian company/companies. The subject company/companies may have been a client/clients of UBS AG, its affiliates or subsidiaries during the 12 months preceding the date of distribution of the research report with respect to investment banking and/or non-investment banking securities-related services and/or non-securities services. With regard to information on associates, please refer to the Annual Report at: http://www.ubs.com/global/en/about_ubs/investor_relations/annualreporting.html

The disclosures contained in research documents produced by UBS Limited shall be governed by and construed in accordance with English law.

UBS specifically prohibits the redistribution of this document in whole or in part without the written permission of UBS and UBS accepts no liability whatsoever for the actions of third parties in this respect. Images may depict objects or elements that are protected by third party copyright, trademarks and other intellectual property rights. © UBS 2016. The key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved.

